Table 5. Univariate and multivariate analyses of prognostic factors correlated with OS and PFS.
| Variables | PFS | OS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | ||||||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||||
| 3D EIT classification (Ic/Ib/Ia) | 2.328 (1.374, 3.944) | 0.006 | 2.836 (1.555, 5.172) | 0.012 | 2.109 (1.088, 4.090) | 0.025 | 2.399 (1.035, 5.564) | 0.041 | |||
| Age (≤40/>40 years) | 1.180 (0.611, 2.282) | 0.622 | – | – | 2.602 (0.972, 6.970) | 0.057 | – | – | |||
| Tumor size (>5/2–5/<2 cm) | 1.283 (0.815, 2.043) | 0.254 | – | – | 1.512 (0.882, 2.592) | 0.133 | – | – | |||
| Vessel embolus (present/absent) | 1.593 (0.815, 3.115) | 0.173 | – | – | 2.136 (0.949, 4.811) | 0.067 | – | – | |||
| Perineural invasion (present/absent) | 1.119 (0.513, 2.442) | 0.777 | – | – | 1.411 (0.560, 3.556) | 0.465 | – | – | |||
| ER (positive/negative) | 0.374 (0.191, 0.731) | 0.001 | 0.279 (0.132, 0.590) | 0.004 | 0.247 (0.098, 0.621) | 0.002 | 0.204 (0.074, 0.561) | 0.008 | |||
| PR (positive/negative) | 0.558 (0.291, 1.070) | 0.079 | – | – | 0.859 (0.481, 2.554) | 0.158 | – | – | |||
| HER2 (positive/negative) | 2.519 (1.314, 4.829) | 0.005 | 2.371 (1.226, 4.584) | 0.010 | 2.326 (1.502, 3.600) | <0.001 | 2.746 (1.208, 6.243) | 0.016 | |||
| LNM (positive/negative) | 2.304 (1.215, 4.369) | 0.011 | 1.511 (0.768, 2.970) | 0.232 | 2.986 (1.306, 6.824) | 0.015 | 1.786 (0.742, 4.300) | 0.196 | |||
| Tumor stage (III/II/I) | 2.267 (1.583, 3.012) | 0.001 | 2.181 (1.336, 4.373) | 0.009 | 1.891 (1.322, 5.023) | 0.012 | 1.648 (1.110, 4.879) | 0.037 | |||
OS, overall survival; PFS, progression free survival; HR, hazard ratio; 95% CI, 95% confidence interval; 3D EIT, three-dimensional electrical impedance tomography; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; LNM, lymph node metastasis.